GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Cash, Cash Equivalents, Marketable Securities

TCRT (Alaunos Therapeutics) Cash, Cash Equivalents, Marketable Securities : $1.68 Mil (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics Cash, Cash Equivalents, Marketable Securities?

Alaunos Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Mar. 2024 ($4.15 Mil) to Jun. 2024 ($2.46 Mil) but then stayed the same from Jun. 2024 ($2.46 Mil) to Sep. 2024 ($1.68 Mil).

Alaunos Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($76.05 Mil) to Dec. 2022 ($39.06 Mil) and declined from Dec. 2022 ($39.06 Mil) to Dec. 2023 ($6.06 Mil).


Alaunos Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Alaunos Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Alaunos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79.74 115.07 76.05 39.06 6.06

Alaunos Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.94 6.06 4.15 2.46 1.68

Alaunos Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Alaunos Therapeutics  (NAS:TCRT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Alaunos Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
2617 Bissonnet Street, Suite 225, Houston, TX, USA, 77005
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129

Alaunos Therapeutics Headlines

From GuruFocus

Q4 2021 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

ZIOPHARM Oncology, Inc. - Special Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024